Eurican Dhppi

Indications for use Active immunisation of dogs to: - prevent mortality and clinical signs caused by canine distemper virus (CDV), - prevent mortality and clinical signs caused by infectious canine hepatitis virus (CAV), - reduce viral excretion during respiratory disease caused by canine adenovirus type 2 (CAV-2), - prevent mortality, clinical signs and viral excretion caused by canine parvovirus (CPV)*, - reduce viral excretion caused by canine parainfluenza virus type 2 (CPiV), Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Current available challenge and serological data show that protection for distemper virus, adenovirus and parvovirus* lasts for 2 years after primary vaccination course followed by a first annual booster. Any decision to adapt the vaccination schedule of this veterinary medicinal product needs to be made on a case by case basis, taking into account the vaccination history of the dog and the epidemiological context. *Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c either by challenge (type 2b) or serology (type 2a and 2c). Contra-indications None. Special warnings for each target species None. Special precautions for use in animals Vaccinate healthy animals only. Apply usual aseptic procedures. After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed without adverse consequence for in-contact animals. Special precautions to be taken by the person administering the product to animals In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician. Adverse reactions Immediately after injection, a slight swelling (≤ 2 cm) may commonly be observed at the injection site, usually regressing within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also be commonly observed. Uncommon reactions such as anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may be observed. As with any vaccine, rare hypersensitivity reactions may occur. In such cases, appropriate symptomatic treatment should be provided. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). Use during pregnancy, lactation or lay Can be used during pregnancy. Interactions Safety and efficacy data are available which demonstrate that this vaccine can be administered with Eurican LR, Eurican L or Eurican Lmulti vaccines (used as diluent) where available. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Rabisin if the vaccine has been reconstituted with Eurican L or Eurican Lmulti. When administered with Boehringer Ingelheim's vaccines containing rabies, the minimum age for vaccination is 12 weeks of age. When administered reconstituted with the Eurican LR vaccine a small and transient nodule (maximum size 1.5 cm) at the injection site may be induced due to the presence of aluminium hydroxide and a slight swelling (~4 cm) may occur after the injection at injection site, regressing generally within 1-4 days. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Vat Rate: 20%